Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 41, Issue 11, 2008, Pages 919-925

  Johnston, P B ^a   Wiseman, G A ^a   Micallef, I N M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FLUORODEOXYGLUCOSE F 18;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; HUMAN; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VALIDATION PROCESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 45449111800     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.82     Document Type: Review

References (16)

1. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
2. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N et al. Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology 1998; 206: 475-481.
3. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.
4. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027.
5. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363.
6. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
7. Bondly C, Johnston PB, Lowe V, Ansell SM, Inwards DJ, Porrata LF et al. Positive positron emission tomography (PET) pre-autologous stem cell transplant (ASCT) in non-Hodgkin lymphoma (NHL) does not preclude successful outcome. Biol Blood Marrow Transplant 2006; 12: 18-19.
8. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260-267.
9. Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 103-111.
10. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of pre-transplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53-59.
11. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME et al Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124: 608-613.
12. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211-216.
13. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110: 1361-1369.
14. Kassim A, Mineishi S, Greer J, Koyama T, Chinratanalab W, Brandt S et al. Post-transplant positron emission tomography using fluorine 18-fluor-deoxyglucose ([18F]FDG-PFT) correlates with outcome in patients with aggressive non-Hodgkin's lymphoma undergoing high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT). Blood 2004; 104: 259a.
15. Alousi A, Saliba R, Okoroji G, Hosing C, Samuels B, Champlin R et al The influence of PET-gallium (PET Gal) status and high-dose rituximab in patients with aggressive, large, b-cell lymphoma (LBCL) receiving autologous stem cell transplants. Blood 2006; 108: 3058a.
16. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109: 486-491.